+

GR3033067T3 - Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis - Google Patents

Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis

Info

Publication number
GR3033067T3
GR3033067T3 GR20000400756T GR20000400756T GR3033067T3 GR 3033067 T3 GR3033067 T3 GR 3033067T3 GR 20000400756 T GR20000400756 T GR 20000400756T GR 20000400756 T GR20000400756 T GR 20000400756T GR 3033067 T3 GR3033067 T3 GR 3033067T3
Authority
GR
Greece
Prior art keywords
atherosclerosis
medicament
prevention
manufacture
nadph oxidase
Prior art date
Application number
GR20000400756T
Other languages
English (en)
Inventor
James A Holland
David K Johnson
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of GR3033067T3 publication Critical patent/GR3033067T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
GR20000400756T 1995-11-27 2000-03-27 Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis GR3033067T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/562,767 US5763496A (en) 1995-11-27 1995-11-27 Prevention of atherosclerosis using NADPH oxidase inhibitors
PCT/US1996/019053 WO1997019679A2 (en) 1995-11-27 1996-11-27 Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis

Publications (1)

Publication Number Publication Date
GR3033067T3 true GR3033067T3 (en) 2000-08-31

Family

ID=24247689

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000400756T GR3033067T3 (en) 1995-11-27 2000-03-27 Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis

Country Status (10)

Country Link
US (2) US5763496A (el)
EP (2) EP0861070B1 (el)
JP (2) JPH11507946A (el)
AT (1) ATE189957T1 (el)
AU (1) AU1085997A (el)
CA (1) CA2238098C (el)
DE (1) DE69606882T2 (el)
ES (1) ES2144792T3 (el)
GR (1) GR3033067T3 (el)
WO (1) WO1997019679A2 (el)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090851A (en) * 1997-09-10 2000-07-18 Johns Hopkins University School Of Medicine Use of an NADPH-oxidase inhibitor in the treatment of reperfusion injury
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
AU782564B2 (en) * 2000-02-09 2005-08-11 Paul A Sneed Treatment of fibromyalgia with Ubiquinone 10 and succinic acid
WO2001089517A2 (en) * 2000-05-19 2001-11-29 Thomas Jefferson University Inhibition of cell proliferation and matrix synthesis by antioxidants and nad(p)h oxidase inhibitors
US6492429B1 (en) * 2000-07-10 2002-12-10 N.V. Nutricia Composition for the treatment of osteoarthritis
AU2001296821A1 (en) * 2000-10-12 2002-04-22 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting angiogenesis using nadph oxidase inhibitors
WO2002053161A1 (en) * 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
DE10104825A1 (de) * 2001-02-01 2002-08-08 Florian Lang Screening von Antimalariamitteln
WO2003037829A2 (en) * 2001-11-01 2003-05-08 Rensselaer Polytechnic Institute Solid-phase array-based biocatalytic transformations
AU2002359790A1 (en) * 2001-12-21 2003-07-15 Charlotte Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center Regulation of nad(p)h oxidase growth and transcription in melanoma cells
US6949586B2 (en) * 2002-02-11 2005-09-27 Council Of Scientific Research Synergistic composition of trans-tetracos-15-enoic acid and Apocynin and method of treatment for hepatotoxicity
AU2003224549A1 (en) * 2002-04-17 2003-10-27 Biovitrum Ab Nad)p)h oxidase inhibitors for increased glucose uptake and treatment of type ii diabetes
WO2003095667A2 (en) * 2002-05-13 2003-11-20 Arexis Ab Autoimmune conditions and nadph oxidase defects
US20040097467A1 (en) * 2002-08-22 2004-05-20 Vijaya Juturu Arginine silicate inositol complex and use thereof
WO2004069201A2 (en) * 2003-02-03 2004-08-19 Medlogics Device Corporation Compounds useful in coating stents to prevent and treat stenosis and restenosis
JP2006520326A (ja) * 2003-02-28 2006-09-07 ハワード フローリー インスティチュート オブ エクスペリメンタル フィジオロジー アンド メディシン 治療薬
TW200509886A (en) * 2003-05-02 2005-03-16 Takara Bio Inc Therapeutic agent
WO2005103297A1 (en) * 2004-03-31 2005-11-03 Georgetown University METHODS AND COMPOSITIONS RELATED TO MODULATION OF p22phox
EP1602926A1 (en) 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
WO2006020912A2 (en) * 2004-08-11 2006-02-23 The Regents Of The University Of California Treatments for congestive heart failure
US8569374B2 (en) 2004-09-16 2013-10-29 The Trustees Of The University Of Pennsylvania NADPH oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US20080051451A1 (en) * 2006-03-15 2008-02-28 Marcel Linschoten Autoimmune conditions and NADPH oxidase defects
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
CA2690913C (en) 2007-06-08 2017-05-23 Mannkind Corporation Ire-1.alpha. inhibitors
KR100989093B1 (ko) * 2008-01-18 2010-10-25 한화제약주식회사 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
US20110236476A1 (en) 2008-09-02 2011-09-29 Amarin Corporation Plc. Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
EP2166010A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
SMT202000647T1 (it) 2009-04-29 2021-01-05 Amarin Pharmaceuticals Ie Ltd Composizione farmaceutica stabile e metodi di utilizzo della stessa
NZ595789A (en) 2009-04-29 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
HUE036736T2 (hu) 2009-06-15 2018-07-30 Amarin Pharmaceuticals Ie Ltd Készítmények és eljárások trigliceridek csökkentésére az LDL-C szintek emelése nélkül egy alanynak sztatin terápiájában
BR112012006692B8 (pt) 2009-09-23 2021-05-25 Amarin Corp Plc composição farmacêutica compreendendo um derivado de hidróxi de atorvastatina e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato
EP2305679A1 (en) 2009-09-28 2011-04-06 GenKyoTex SA Pyrazoline dione derivatives as nadph oxidase inhibitors
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ757815A (en) 2010-11-29 2020-05-29 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
WO2013136277A1 (en) 2012-03-13 2013-09-19 Unimark Remedies Ltd. Pharmaceutical compositions for treatment of cardiovascular diseases
US20140080850A1 (en) * 2012-06-05 2014-03-20 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising an omega-3 fatty acid and a hydroxy-derivative of a statin and methods of using same
NZ703267A (en) 2012-06-29 2017-01-27 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
WO2014183184A1 (en) * 2013-05-14 2014-11-20 University Of Prince Edward Island Compositions and methods for treating cardiometabolic diseases and disorders
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
EP3034500A1 (en) 2014-12-17 2016-06-22 Genkyotex Sa Amido thiazole derivatives as NADPH oxidase inhibitors
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CN109890384A (zh) 2016-09-01 2019-06-14 Jds治疗有限公司 生物素镁组合物和使用方法
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
EP3479843A1 (en) 2017-11-01 2019-05-08 GenKyoTex Suisse SA Use of nox inhibitors for treatment of cancer
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
AU2019349563B2 (en) 2018-09-24 2023-06-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
CA3118583C (en) 2018-11-02 2024-05-14 Nutrition 21, Llc Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers
GB2613672A (en) 2019-12-16 2023-06-14 Nutrition 21 Llc Methods of production of aginine-silicate complexes
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593966A (en) * 1989-03-31 1997-01-14 The United States Of America As Represented By The Department Of Health And Human Services Peptide derivatives of cytochrome b558 and their use as medicaments
DE4109627A1 (de) * 1991-03-23 1992-09-24 Boehringer Mannheim Gmbh Neue phenolether, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
GB9200623D0 (en) * 1992-01-13 1992-03-11 Bayer Ag Benzofuranyl and thiophenyl-methylthio-alkanecarboxylic acid derivatives
US5244916A (en) * 1992-01-31 1993-09-14 The Scripps Research Institute Inhibition of respiratory burst using posttranslational modification inhibitors
JPH06135880A (ja) * 1992-10-30 1994-05-17 Kanebo Ltd 活性酸素消去剤
JP3023254B2 (ja) * 1992-11-05 2000-03-21 鐘紡株式会社 メラニン生成抑制剤
JPH06227977A (ja) * 1993-02-01 1994-08-16 Suntory Ltd 活性酸素消去剤
WO1995013063A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
JPH07165575A (ja) * 1993-12-08 1995-06-27 Nippon Oil & Fats Co Ltd ヒドロキノン誘導体
JP2774063B2 (ja) * 1993-12-24 1998-07-09 鐘紡株式会社 抗酸化組成物

Also Published As

Publication number Publication date
US5763496A (en) 1998-06-09
JPH11507946A (ja) 1999-07-13
EP0914821A2 (en) 1999-05-12
CA2238098A1 (en) 1997-06-05
DE69606882T2 (de) 2000-08-17
EP0861070A2 (en) 1998-09-02
US5902831A (en) 1999-05-11
AU1085997A (en) 1997-06-19
JP2003176224A (ja) 2003-06-24
EP0914821A3 (en) 2000-04-26
ES2144792T3 (es) 2000-06-16
DE69606882D1 (de) 2000-04-06
CA2238098C (en) 2001-01-30
WO1997019679A3 (en) 1997-08-28
WO1997019679A2 (en) 1997-06-05
ATE189957T1 (de) 2000-03-15
EP0861070B1 (en) 2000-03-01

Similar Documents

Publication Publication Date Title
GR3033067T3 (en) Use of nadph oxidase inhibitors for the manufacture of a medicament for prevention of atherosclerosis
HUP0104966A3 (en) A medical system and a method of controlling the system for use by a patient for medical self treatment
AU4594796A (en) System and method for diagnosis of living tissue diseases
AU4355497A (en) Apparatus responsive to movement of a patient during treatment/diagnosis
EP0676709A3 (en) Method and device for adapting the display of physiological sizes of a patient on a medical monitor.
AU689985B2 (en) Oscillometric blood pressure monitor which automatically determines when to take blood pressure measurements
EP0686203A4 (en) COMPOUNDS AND METHODS RELATING TO THE DIAGNOSIS, TREATMENT AND PREVENTION OF CELL DEATH DISEASES
HK1043306A1 (en) 16-phenoxy-lipoxin analogs for medical use
IL128877A0 (en) Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
AU2002226690A1 (en) Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases
AU3198589A (en) A method for treatment of hypercortisolemic, depressed patients
AU9742898A (en) Demonstration device modelling a living organism
AU8742198A (en) Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity
AU3861989A (en) Method for the treatment and the diagnosis of coronary heart disease
AU4525596A (en) An interactive system using a graphical interface for assisting medical professionals in the diagnosis, treatment and management of surgical and trauma patients
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
AU2909495A (en) Evaluation of blood coagulation activity
AU8204182A (en) Apparatus for the medical treatment of living organisms, particularly human beings
DE69405284D1 (de) Manschette für Blutdruckmesser
WO2003060467A3 (en) Method for analyzing effects of medical agents
AU4527596A (en) Methods for treatment or diagnosis of diseases or disorders associated with an apb domain
AU1726495A (en) Pyridinoline crosslinks as markers of periodontal and peri-implant disease activity
EP1304107A3 (en) Use of oxazolidinines derivatives for treating psoriasis
EP1321146A3 (en) Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use
AU3651595A (en) Drug for the prevention and treatment of auto-immune and viral diseases, and diagnostic agents for detecting said diseases

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载